hotspot -WSS

hotspot

author：explore 2025-09-30 22:04:12 - browse：8438

After a drawn-out lobbying fight, ARPA-H chose its headquarters: a hub and spokes model, with three central locations in Boston, Texas, and D.C. David L. Ryan/Boston Globe

WASHINGTON — Cities and states have been clamoring to play host to the Advanced Research Projects Agency for Health since before the agency existed — before, in fact, anyone truly knew what ARPA-H was.

But the lobbying campaign from universities, business leaders, members of Congress, and big-city mayors is finally over.

The end came not with a dramatic reveal or a formal ribbon-cutting, but with a largely bureaucratic and anticlimactic announcement that the Biden administration plans to share the wealth. ARPA-H will be housed in a hub-and-spoke model across three major metro areas: The D.C. suburbs; Cambridge, Mass.; and Dallas. Additional “spokes,” the agency announced Tuesday, will be spread across the country at 10 sites spanning from Florida to Alaska.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： My yearlong odyssey to get my son’s ADHD medication covered

hotspot

WSS

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Why doctors need education on FDA device approval process

Ionis drug prevents swelling attacks due to hereditary angioedema

Elizabeth Holmes banned from government health programs

Think you might have Covid

entertainment

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

BMI, flaws aside, is found to be useful estimate of body fat in youth

Hollywood unions extend contract negotiations for actors

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

In age of alternative facts, a scholarly course on calling out crap

Change Healthcare can notify patients about the breach, HHS says

Medical leaders decry Supreme Court decision on affirmative action

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Letters to First Opinion on caregivers, digital health, and more

Wikipedia

Intellia reports positive results for its CRISPR

Ultragenyx gene therapy for rare liver ailment succeeds in late

With trial win, GSK could get blood cancer drug back on market

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Why doctors need education on FDA device approval process

hotspot

entertainment

focus

leisure time